Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 16 studies | 59% ± 20% | |
lung | 10 studies | 27% ± 11% | |
peripheral blood | 10 studies | 24% ± 6% | |
eye | 10 studies | 53% ± 27% | |
heart | 6 studies | 35% ± 13% | |
liver | 5 studies | 46% ± 17% | |
adipose | 4 studies | 50% ± 26% | |
skin | 4 studies | 33% ± 13% | |
kidney | 3 studies | 73% ± 15% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 12075.91 | 258 / 258 | 99% | 9.81 | 227 / 230 |
thymus | 99% | 3345.80 | 647 / 653 | 97% | 5.77 | 584 / 605 |
liver | 99% | 3759.72 | 224 / 226 | 94% | 5.07 | 382 / 406 |
breast | 97% | 2750.33 | 446 / 459 | 95% | 4.04 | 1060 / 1118 |
esophagus | 99% | 3638.24 | 1435 / 1445 | 92% | 5.68 | 168 / 183 |
lung | 98% | 4181.08 | 567 / 578 | 92% | 4.67 | 1068 / 1155 |
prostate | 93% | 2100.14 | 227 / 245 | 94% | 3.26 | 472 / 502 |
pancreas | 90% | 2167.64 | 296 / 328 | 94% | 4.29 | 167 / 178 |
kidney | 78% | 1600.13 | 69 / 89 | 97% | 8.55 | 874 / 901 |
uterus | 97% | 2810.32 | 165 / 170 | 75% | 2.67 | 344 / 459 |
brain | 68% | 1579.49 | 1784 / 2642 | 99% | 6.50 | 698 / 705 |
ovary | 99% | 3424.35 | 179 / 180 | 63% | 1.35 | 272 / 430 |
bladder | 90% | 2257.14 | 19 / 21 | 53% | 1.58 | 266 / 504 |
skin | 93% | 20417.61 | 1683 / 1809 | 50% | 1.39 | 235 / 472 |
intestine | 89% | 2629.27 | 861 / 966 | 53% | 1.49 | 277 / 527 |
stomach | 71% | 1455.68 | 255 / 359 | 70% | 2.29 | 201 / 286 |
muscle | 100% | 10663.95 | 803 / 803 | 0% | 0 | 0 / 0 |
adipose | 98% | 3121.62 | 1180 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 97% | 2709.82 | 1293 / 1335 | 0% | 0 | 0 / 0 |
spleen | 96% | 2180.82 | 231 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 91% | 4.87 | 41 / 45 |
heart | 72% | 1451.18 | 621 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 62% | 2.45 | 18 / 29 |
peripheral blood | 45% | 1373.42 | 418 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 31% | 0.66 | 25 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0008589 | Biological process | regulation of smoothened signaling pathway |
GO_0070328 | Biological process | triglyceride homeostasis |
GO_0001525 | Biological process | angiogenesis |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_0021702 | Biological process | cerebellar Purkinje cell differentiation |
GO_0019218 | Biological process | regulation of steroid metabolic process |
GO_0072539 | Biological process | T-helper 17 cell differentiation |
GO_0036315 | Biological process | cellular response to sterol |
GO_0042692 | Biological process | muscle cell differentiation |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0071456 | Biological process | cellular response to hypoxia |
GO_0045599 | Biological process | negative regulation of fat cell differentiation |
GO_0030522 | Biological process | intracellular receptor signaling pathway |
GO_0043030 | Biological process | regulation of macrophage activation |
GO_0010906 | Biological process | regulation of glucose metabolic process |
GO_0046068 | Biological process | cGMP metabolic process |
GO_0071347 | Biological process | cellular response to interleukin-1 |
GO_0032922 | Biological process | circadian regulation of gene expression |
GO_0042632 | Biological process | cholesterol homeostasis |
GO_0071356 | Biological process | cellular response to tumor necrosis factor |
GO_0050728 | Biological process | negative regulation of inflammatory response |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0021930 | Biological process | cerebellar granule cell precursor proliferation |
GO_0042753 | Biological process | positive regulation of circadian rhythm |
GO_0006809 | Biological process | nitric oxide biosynthetic process |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0010575 | Biological process | positive regulation of vascular endothelial growth factor production |
GO_0043124 | Biological process | negative regulation of canonical NF-kappaB signal transduction |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005730 | Cellular component | nucleolus |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0000977 | Molecular function | RNA polymerase II transcription regulatory region sequence-specific DNA binding |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0043565 | Molecular function | sequence-specific DNA binding |
GO_0004879 | Molecular function | nuclear receptor activity |
GO_0001221 | Molecular function | transcription coregulator binding |
GO_0001222 | Molecular function | transcription corepressor binding |
GO_0008013 | Molecular function | beta-catenin binding |
GO_0001223 | Molecular function | transcription coactivator binding |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_0008142 | Molecular function | oxysterol binding |
GO_0005515 | Molecular function | protein binding |
GO_0098531 | Molecular function | ligand-activated transcription factor activity |
Gene name | RORA |
Protein name | Nuclear receptor ROR-alpha (Nuclear receptor RZR-alpha) (Nuclear receptor subfamily 1 group F member 1) (RAR-related orphan receptor A) (Retinoid-related orphan receptor-alpha) RAR related orphan receptor A (RAR-related orphan receptor A, isoform CRA_c) RAR related orphan receptor A |
Synonyms | RZRA hCG_1787044 NR1F1 |
Description | FUNCTION: Nuclear receptor that binds DNA as a monomer to ROR response elements (RORE) containing a single core motif half-site 5'-AGGTCA-3' preceded by a short A-T-rich sequence. Key regulator of embryonic development, cellular differentiation, immunity, circadian rhythm as well as lipid, steroid, xenobiotics and glucose metabolism. Considered to have intrinsic transcriptional activity, have some natural ligands like oxysterols that act as agonists (25-hydroxycholesterol) or inverse agonists (7-oxygenated sterols), enhancing or repressing the transcriptional activity, respectively. Recruits distinct combinations of cofactors to target genes regulatory regions to modulate their transcriptional expression, depending on the tissue, time and promoter contexts. Regulates genes involved in photoreceptor development including OPN1SW, OPN1SM and ARR3 and skeletal muscle development with MYOD1. Required for proper cerebellum development . Regulates SHH gene expression, among others, to induce granule cells proliferation as well as expression of genes involved in calcium-mediated signal transduction. Regulates the circadian expression of several clock genes, including CLOCK, BMAL1, NPAS2 and CRY1. Competes with NR1D1 for binding to their shared DNA response element on some clock genes such as BMAL1, CRY1 and NR1D1 itself, resulting in NR1D1-mediated repression or RORA-mediated activation of clock genes expression, leading to the circadian pattern of clock genes expression. Therefore influences the period length and stability of the clock. Regulates genes involved in lipid metabolism such as apolipoproteins APOA1, APOA5, APOC3 and PPARG. In liver, has specific and redundant functions with RORC as positive or negative modulator of expression of genes encoding phase I and phase II proteins involved in the metabolism of lipids, steroids and xenobiotics, such as CYP7B1 and SULT2A1. Induces a rhythmic expression of some of these genes. In addition, interplays functionally with NR1H2 and NR1H3 for the regulation of genes involved in cholesterol metabolism. Also involved in the regulation of hepatic glucose metabolism through the modulation of G6PC1 and PCK1. In adipose tissue, plays a role as negative regulator of adipocyte differentiation, probably acting through dual mechanisms. May suppress CEBPB-dependent adipogenesis through direct interaction and PPARG-dependent adipogenesis through competition for DNA-binding. Downstream of IL6 and TGFB and synergistically with RORC isoform 2, is implicated in the lineage specification of uncommitted CD4(+) T-helper (T(H)) cells into T(H)17 cells, antagonizing the T(H)1 program. Probably regulates IL17 and IL17F expression on T(H) by binding to the essential enhancer conserved non-coding sequence 2 (CNS2) in the IL17-IL17F locus. Involved in hypoxia signaling by interacting with and activating the transcriptional activity of HIF1A. May inhibit cell growth in response to cellular stress. May exert an anti-inflammatory role by inducing CHUK expression and inhibiting NF-kappa-B signaling. . |
Accessions | ENST00000559343.1 ENST00000261523.9 [P35398-1] H0YLS5 ENST00000551975.5 A0A087X2G0 ENST00000558904.2 ENST00000335670.11 [P35398-2] ENST00000449337.6 A0A0C4DFP5 A0A0C4DG53 H0YII6 P35398 ENST00000309157.8 |